Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Rio Piedras, Puerto Rico Clinical Trials

A listing of Rio Piedras, Puerto Rico clinical trials actively recruiting patients volunteers.

RESULTS

Found (7) clinical trials

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

The main purpose of this Phase 1/2 study is to determine the safety and efficacy of pegzilarginase in combination with pembrolizumab in patients with ED-SCLC who have relapsed or progressive disease on or within 6 months of platinum-based chemotherapy.

Phase

1.81 miles

Learn More »

Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission

The purpose of this study is to explore the effects of early intensive antiretroviral therapy (ART) on achieving HIV remission (HIV RNA below the limit of detection of the assay) among HIV-infected infants. The study will enroll two cohorts. Cohort 1 will include infants at high risk for in utero ...

Phase

4.37 miles

Learn More »

Evaluating the Pharmacokinetics Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents

This study will evaluate the pharmacokinetics (PK), safety, and tolerability of DOR and DOR/3TC/TDF in HIV-1-infected children and adolescents. This study will be conducted in two cohorts: Cohort 1 and Cohort 2. At study entry (Day 0), participants in Cohort 1 will receive a single dose of DOR added to ...

Phase

4.37 miles

Learn More »

Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in HIV-1-infected Participants on Suppressive cART

This study will evaluate the safety and immunotherapeutic activity of an anti-PD-1 antibody (cemiplimab) in HIV-1-infected participants on combination antiretroviral therapy (cART) who have HIV-1 RNA below the limit of quantification and CD4+ T cell counts greater than or equal to 350/mm^3. Participants will be enrolled into three sequential dose-rising ...

Phase

4.37 miles

Learn More »

More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents

This study will confirm the dose and evaluate the safety, acceptability, tolerability, and pharmacokinetics (PK) of oral cabotegravir (CAB), long-acting injectable cabotegravir (CAB LA), and long-acting injectable rilpivirine (RPV LA) in virologically suppressed HIV1 infected children and adolescents aged 12 to less than 18 years. The study will include two ...

Phase

4.37 miles

Learn More »

HIV-1-Gag Conserved-Element DNA Vaccine as Therapeutic Vaccination in HIV-Infected Persons With Viral Suppression on Antiretroviral Therapy

This study will evaluate the safety, immunogenicity, and preliminary assessment of efficacy of a novel vaccine encoding conserved elements (CE) of the HIV-1 Gag core protein, p24Gag, as a therapeutic vaccine in HIV-1 infected persons who are on antiretroviral therapy (ART). The study will randomly assign participants to one of ...

Phase

4.37 miles

Learn More »

Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants Children and Adolescents

DTG is an HIV medicine in the integrase inhibitor drug class. The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of DTG in HIV-1 infected infants, children, and adolescents. Participation in this study will last approximately 48 weeks, followed by long-term safety follow-up that ...

Phase

6.82 miles

Learn More »